News

New lipid guidelines sharpen LDL goals for diabetes, HIV, CKD, cancer survivors and seniors, highlighting statins’ power and shared decisions.

New lipid guidance brings back LDL targets by risk, pairing percent reduction with absolute goals—and explains why lower is better.

New US guidance spotlights one-time lipoprotein(a) tests and ApoB targets to uncover hidden heart risk and fine-tune lipid therapy.

New guidance shows how risk enhancers and coronary calcium scores refine statin decisions, including handling incidental CAC on routine CT scans.

New ACC/AHA lipid update explains PREVENT risk equations, updated thresholds, and when to start statins or CAC scoring to prevent heart attacks.

This episode features discussion around 3 recent announcements from Novo Nordisk, Eli Lilly, and Structure Therapeutics.

In this Q&A, Linda Stein Gold, MD, shares her views on the clinical significance of icotrokinra's FDA approval and the data leading to this approval.

New study finds GLP-1 RAs are associated with lower anxiety, suicidality, and sick leave in patients with diabetes and mental illness.

Stay updated with the latest healthcare breakthroughs, including FDA actions and new phase 3 data, in this week’s essential news roundup.

After the oral IL-23 inhibitor icotrokinra's (Icotyde) FDA approval, this interview covers what primary care clinicians should conclude.

Hosts reveal how research, mentors, and clinic rotations spark a passion for skin disease and what makes dermatology unique.

Deepak Bhatt, MD, MPH, MBA, discusses 4 trials to watch at the upcoming ACC.26.

Findings suggest psychedelics match antidepressants for symptom relief, with future research needed on real-world use and functional outcomes.

GLP-1 discontinuation increases major adverse cardiovascular event risk in type 2 diabetes, highlighting the need for continuous therapy to sustain cardiometabolic benefit.

Clinicians compare newest asthma/COPD biologics, highlighting dupilumab’s edge, biomarker shifts, and insurance barriers shaping real-world use.

Linda Stein Gold, MD, shares her perspective on the clinical significance of icotrokinra's FDA approval and what dermatologists need to know.

FDA clears setmelanotide for acquired hypothalamic obesity for ages 4 years and older, delivering 15.8% BMI drop in TRANSCEND.

A clip from an episode of ABCs in Dermatology showcases perspective into the personal lives of hosts Chris Bunick, MD, PhD, and Lindsay Ackerman, MD.

Kichler notes that EPI is frequently overlooked in patients with symptoms resembling IBD or celiac disease and offers key insights on diagnosis and management.

The IBAT inhibitor’s approval, the first for this indication, was based on data from the GLISTEN trial showing reductions in cholestatic pruritus and itch-related sleep interference.

Shamji shared the factors influencing which treatments are best for each patient and further research he'd like to see.

Meta-analysis shows psychedelic-assisted therapy offers similar symptom improvement to open-label antidepressants under equal unblinding conditions.

The approval is based on results from the STEP UP trial program showing substantial weight loss in adults with obesity.

AI-enabled ECG may help detect liver disease earlier, offering a new path to close diagnostic gaps and shift toward preventive hepatology in clinical practice.

Su described how NNAALs drive management decisions in pregnancy and post partum care.

The first-in-class GIP, GLP-1 and glucagon triple hormone receptor agonist delivered superior A1C reduction and weight loss at 40 weeks in people with type 2 diabetes.